The global market for Long Acting Beta 2 Agonist was valued at US$ 2312 million in the year 2024 and is projected to reach a revised size of US$ 2931 million by 2031, growing at a CAGR of 3.5% during the forecast period.

Long Acting Beta 2 Agonist Market

Salmeterol and formoterol are both long-acting beta(2)-adrenoceptor agonists (beta(2)-agonists).

The inhalation combination product market is driven by the increasing prevalence of respiratory diseases such as asthma and chronic obstructive pulmonary disease (COPD) and the demand for more effective and convenient treatment options. Inhalation combination products offer a combination of two or more medications in a single device, providing patients with better disease management and improved treatment adherence. These products offer advantages such as simplified dosing regimens, enhanced efficacy, and reduced side effects compared to multiple separate inhalers. Additionally, advancements in inhalation technology, such as metered-dose inhalers and dry powder inhalers, have further fueled the adoption of combination products. However, the market also faces challenges, including the complexity of formulation development and the need for rigorous testing to ensure compatibility and stability of the combined medications. Moreover, regulatory requirements for combination products can be more stringent than individual drugs, making the approval process more challenging. To succeed in this market, manufacturers must invest in research and development to optimize combination therapies, address regulatory concerns, and educate healthcare professionals and patients about the benefits of inhalation combination products.

Report Scope

This report aims to provide a comprehensive presentation of the global market for Long Acting Beta 2 Agonist, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Long Acting Beta 2 Agonist.

The Long Acting Beta 2 Agonist market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Long Acting Beta 2 Agonist market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.

For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.

The report will help the Long Acting Beta 2 Agonist manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.

Scope of Long Acting Beta 2 Agonist Market Report

Report Metric	Details
Report Name	Long Acting Beta 2 Agonist Market
Accounted market size in year	US$ 2312 million
Forecasted market size in 2031	US$ 2931 million
CAGR	3.5%
Base Year	year
Forecasted years	2025 - 2031
Segment by Type	Serevent Foradil Other
Segment by Application	COPD Asthma Other
Consumption by Region	North America (United States, Canada) Europe (Germany, France, UK, Italy, Russia) Asia-Pacific (China, Japan, South Korea, Taiwan) Southeast Asia (India) Latin America (Mexico, Brazil)
By Company	GSK, AstraZeneca, Chiesi, Boehringer Ingelheim, Novartis, Teva, Organon
Forecast units	USD million in value
Report coverage	Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Core Chapters

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Long Acting Beta 2 Agonist manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Long Acting Beta 2 Agonist in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.

FAQ for this report

How fast is Long Acting Beta 2 Agonist Market growing?

Ans: The Long Acting Beta 2 Agonist Market witnessing a CAGR of 3.5% during the forecast period 2025-2031.

What is the Long Acting Beta 2 Agonist Market size in 2031?

Ans: The Long Acting Beta 2 Agonist Market size in 2031 will be US$ 2931 million.

Who are the main players in the Long Acting Beta 2 Agonist Market report?

Ans: The main players in the Long Acting Beta 2 Agonist Market are GSK, AstraZeneca, Chiesi, Boehringer Ingelheim, Novartis, Teva, Organon

What are the Application segmentation covered in the Long Acting Beta 2 Agonist Market report?

Ans: The Applications covered in the Long Acting Beta 2 Agonist Market report are COPD, Asthma, Other

What are the Type segmentation covered in the Long Acting Beta 2 Agonist Market report?

Ans: The Types covered in the Long Acting Beta 2 Agonist Market report are Serevent, Foradil, Other

1 Long Acting Beta 2 Agonist Market Overview

1.1 Product Definition

1.2 Long Acting Beta 2 Agonist by Type

1.2.1 Global Long Acting Beta 2 Agonist Market Value Comparison by Type (2024 VS 2031)

1.2.2 Serevent

1.2.3 Foradil

1.2.4 Other

1.3 Long Acting Beta 2 Agonist by Application

1.3.1 Global Long Acting Beta 2 Agonist Market Value by Application (2024 VS 2031)

1.3.2 COPD

1.3.3 Asthma

1.3.4 Other

1.4 Global Long Acting Beta 2 Agonist Market Size Estimates and Forecasts

1.4.1 Global Long Acting Beta 2 Agonist Revenue 2020-2031

1.4.2 Global Long Acting Beta 2 Agonist Sales 2020-2031

1.4.3 Global Long Acting Beta 2 Agonist Market Average Price (2020-2031)

1.5 Assumptions and Limitations

2 Long Acting Beta 2 Agonist Market Competition by Manufacturers

2.1 Global Long Acting Beta 2 Agonist Sales Market Share by Manufacturers (2020-2025)

2.2 Global Long Acting Beta 2 Agonist Revenue Market Share by Manufacturers (2020-2025)

2.3 Global Long Acting Beta 2 Agonist Average Price by Manufacturers (2020-2025)

2.4 Global Key Players of Long Acting Beta 2 Agonist, Industry Ranking, 2022 VS 2023 VS 2024

2.5 Global Key Manufacturers of Long Acting Beta 2 Agonist, Manufacturing Sites & Headquarters

2.6 Global Key Manufacturers of Long Acting Beta 2 Agonist, Product Type & Application

2.7 Global Key Manufacturers of Long Acting Beta 2 Agonist, Date of Enter into This Industry

2.8 Global Long Acting Beta 2 Agonist Market Competitive Situation and Trends

2.8.1 Global Long Acting Beta 2 Agonist Market Concentration Rate

2.8.2 The Global 5 and 10 Largest Long Acting Beta 2 Agonist Players Market Share by Revenue

2.8.3 Global Long Acting Beta 2 Agonist Market Share by Company Type (Tier 1, Tier 2, and Tier 3)

2.9 Manufacturers Mergers & Acquisitions, Expansion Plans

3 Global Long Acting Beta 2 Agonist Market Scenario by Region

3.1 Global Long Acting Beta 2 Agonist Market Size by Region: 2020 Versus 2024 Versus 2031

3.2 Global Long Acting Beta 2 Agonist Sales by Region: 2020-2031

3.2.1 Global Long Acting Beta 2 Agonist Sales by Region: 2020-2025

3.2.2 Global Long Acting Beta 2 Agonist Sales by Region: 2026-2031

3.3 Global Long Acting Beta 2 Agonist Revenue by Region: 2020-2031

3.3.1 Global Long Acting Beta 2 Agonist Revenue by Region: 2020-2025

3.3.2 Global Long Acting Beta 2 Agonist Revenue by Region: 2026-2031

3.4 North America Long Acting Beta 2 Agonist Market Facts & Figures by Country

3.4.1 North America Long Acting Beta 2 Agonist Market Size by Country: 2020 VS 2024 VS 2031

3.4.2 North America Long Acting Beta 2 Agonist Sales by Country (2020-2031)

3.4.3 North America Long Acting Beta 2 Agonist Revenue by Country (2020-2031)

3.4.4 United States

3.4.5 Canada

3.5 Europe Long Acting Beta 2 Agonist Market Facts & Figures by Country

3.5.1 Europe Long Acting Beta 2 Agonist Market Size by Country: 2020 VS 2024 VS 2031

3.5.2 Europe Long Acting Beta 2 Agonist Sales by Country (2020-2031)

3.5.3 Europe Long Acting Beta 2 Agonist Revenue by Country (2020-2031)

3.5.4 Germany

3.5.5 France

3.5.6 U.K.

3.5.7 Italy

3.5.8 Russia

3.6 Asia Pacific Long Acting Beta 2 Agonist Market Facts & Figures by Region

3.6.1 Asia Pacific Long Acting Beta 2 Agonist Market Size by Region: 2020 VS 2024 VS 2031

3.6.2 Asia Pacific Long Acting Beta 2 Agonist Sales by Region (2020-2031)

3.6.3 Asia Pacific Long Acting Beta 2 Agonist Revenue by Region (2020-2031)

3.6.4 China

3.6.5 Japan

3.6.6 South Korea

3.6.7 India

3.6.8 Australia

3.6.9 China Taiwan

3.6.10 Southeast Asia

3.7 Latin America Long Acting Beta 2 Agonist Market Facts & Figures by Country

3.7.1 Latin America Long Acting Beta 2 Agonist Market Size by Country: 2020 VS 2024 VS 2031

3.7.2 Latin America Long Acting Beta 2 Agonist Sales by Country (2020-2031)

3.7.3 Latin America Long Acting Beta 2 Agonist Revenue by Country (2020-2031)

3.7.4 Mexico

3.7.5 Brazil

3.7.6 Argentina

3.8 Middle East and Africa Long Acting Beta 2 Agonist Market Facts & Figures by Country

3.8.1 Middle East and Africa Long Acting Beta 2 Agonist Market Size by Country: 2020 VS 2024 VS 2031

3.8.2 Middle East and Africa Long Acting Beta 2 Agonist Sales by Country (2020-2031)

3.8.3 Middle East and Africa Long Acting Beta 2 Agonist Revenue by Country (2020-2031)

3.8.4 Turkey

3.8.5 Saudi Arabia

3.8.6 UAE

4 Segment by Type

4.1 Global Long Acting Beta 2 Agonist Sales by Type (2020-2031)

4.1.1 Global Long Acting Beta 2 Agonist Sales by Type (2020-2025)

4.1.2 Global Long Acting Beta 2 Agonist Sales by Type (2026-2031)

4.1.3 Global Long Acting Beta 2 Agonist Sales Market Share by Type (2020-2031)

4.2 Global Long Acting Beta 2 Agonist Revenue by Type (2020-2031)

4.2.1 Global Long Acting Beta 2 Agonist Revenue by Type (2020-2025)

4.2.2 Global Long Acting Beta 2 Agonist Revenue by Type (2026-2031)

4.2.3 Global Long Acting Beta 2 Agonist Revenue Market Share by Type (2020-2031)

4.3 Global Long Acting Beta 2 Agonist Price by Type (2020-2031)

5 Segment by Application

5.1 Global Long Acting Beta 2 Agonist Sales by Application (2020-2031)

5.1.1 Global Long Acting Beta 2 Agonist Sales by Application (2020-2025)

5.1.2 Global Long Acting Beta 2 Agonist Sales by Application (2026-2031)

5.1.3 Global Long Acting Beta 2 Agonist Sales Market Share by Application (2020-2031)

5.2 Global Long Acting Beta 2 Agonist Revenue by Application (2020-2031)

5.2.1 Global Long Acting Beta 2 Agonist Revenue by Application (2020-2025)

5.2.2 Global Long Acting Beta 2 Agonist Revenue by Application (2026-2031)

5.2.3 Global Long Acting Beta 2 Agonist Revenue Market Share by Application (2020-2031)

5.3 Global Long Acting Beta 2 Agonist Price by Application (2020-2031)

6 Key Companies Profiled

6.1 GSK

6.1.1 GSK Company Information

6.1.2 GSK Description and Business Overview

6.1.3 GSK Long Acting Beta 2 Agonist Sales, Revenue and Gross Margin (2020-2025)

6.1.4 GSK Long Acting Beta 2 Agonist Product Portfolio

6.1.5 GSK Recent Developments/Updates

6.2 AstraZeneca

6.2.1 AstraZeneca Company Information

6.2.2 AstraZeneca Description and Business Overview

6.2.3 AstraZeneca Long Acting Beta 2 Agonist Sales, Revenue and Gross Margin (2020-2025)

6.2.4 AstraZeneca Long Acting Beta 2 Agonist Product Portfolio

6.2.5 AstraZeneca Recent Developments/Updates

6.3 Chiesi

6.3.1 Chiesi Company Information

6.3.2 Chiesi Description and Business Overview

6.3.3 Chiesi Long Acting Beta 2 Agonist Sales, Revenue and Gross Margin (2020-2025)

6.3.4 Chiesi Long Acting Beta 2 Agonist Product Portfolio

6.3.5 Chiesi Recent Developments/Updates

6.4 Boehringer Ingelheim

6.4.1 Boehringer Ingelheim Company Information

6.4.2 Boehringer Ingelheim Description and Business Overview

6.4.3 Boehringer Ingelheim Long Acting Beta 2 Agonist Sales, Revenue and Gross Margin (2020-2025)

6.4.4 Boehringer Ingelheim Long Acting Beta 2 Agonist Product Portfolio

6.4.5 Boehringer Ingelheim Recent Developments/Updates

6.5 Novartis

6.5.1 Novartis Company Information

6.5.2 Novartis Description and Business Overview

6.5.3 Novartis Long Acting Beta 2 Agonist Sales, Revenue and Gross Margin (2020-2025)

6.5.4 Novartis Long Acting Beta 2 Agonist Product Portfolio

6.5.5 Novartis Recent Developments/Updates

6.6 Teva

6.6.1 Teva Company Information

6.6.2 Teva Description and Business Overview

6.6.3 Teva Long Acting Beta 2 Agonist Sales, Revenue and Gross Margin (2020-2025)

6.6.4 Teva Long Acting Beta 2 Agonist Product Portfolio

6.6.5 Teva Recent Developments/Updates

6.7 Organon

6.7.1 Organon Company Information

6.7.2 Organon Description and Business Overview

6.7.3 Organon Long Acting Beta 2 Agonist Sales, Revenue and Gross Margin (2020-2025)

6.7.4 Organon Long Acting Beta 2 Agonist Product Portfolio

6.7.5 Organon Recent Developments/Updates

7 Industry Chain and Sales Channels Analysis

7.1 Long Acting Beta 2 Agonist Industry Chain Analysis

7.2 Long Acting Beta 2 Agonist Raw Material Supply Analysis

7.2.1 Key Raw Materials

7.2.2 Raw Materials Key Suppliers

7.3 Long Acting Beta 2 Agonist Production Mode & Process Analysis

7.4 Long Acting Beta 2 Agonist Sales and Marketing

7.4.1 Long Acting Beta 2 Agonist Sales Channels

7.4.2 Long Acting Beta 2 Agonist Distributors

7.5 Long Acting Beta 2 Agonist Customer Analysis

8 Long Acting Beta 2 Agonist Market Dynamics

8.1 Long Acting Beta 2 Agonist Industry Trends

8.2 Long Acting Beta 2 Agonist Market Drivers

8.3 Long Acting Beta 2 Agonist Market Challenges

8.4 Long Acting Beta 2 Agonist Market Restraints

9 Research Findings and Conclusion

10 Methodology and Data Source

10.1 Methodology/Research Approach

10.1.1 Research Programs/Design

10.1.2 Market Size Estimation

10.1.3 Market Breakdown and Data Triangulation

10.2 Data Source

10.2.1 Secondary Sources

10.2.2 Primary Sources

10.3 Author List

10.4 Disclaimer

FEATURED COMPANIES

List of Tables

Table 1. Global Long Acting Beta 2 Agonist Market Value Comparison by Type (2024 VS 2031) & (US$ Million)

Table 2. Global Long Acting Beta 2 Agonist Market Value by Application (2024 VS 2031) & (US$ Million)

Table 3. Global Long Acting Beta 2 Agonist Market Competitive Situation by Manufacturers in 2024

Table 4. Global Long Acting Beta 2 Agonist Sales (K Units) of Key Manufacturers (2020-2025)

Table 5. Global Long Acting Beta 2 Agonist Sales Market Share by Manufacturers (2020-2025)

Table 6. Global Long Acting Beta 2 Agonist Revenue (US$ Million) by Manufacturers (2020-2025)

Table 7. Global Long Acting Beta 2 Agonist Revenue Share by Manufacturers (2020-2025)

Table 8. Global Market Long Acting Beta 2 Agonist Average Price (US$/Unit) of Key Manufacturers (2020-2025)

Table 9. Global Key Players of Long Acting Beta 2 Agonist, Industry Ranking, 2022 VS 2023 VS 2024

Table 10. Global Key Manufacturers of Long Acting Beta 2 Agonist, Manufacturing Sites & Headquarters

Table 11. Global Key Manufacturers of Long Acting Beta 2 Agonist, Product Type & Application

Table 12. Global Key Manufacturers of Long Acting Beta 2 Agonist, Date of Enter into This Industry

Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)

Table 14. Global Long Acting Beta 2 Agonist by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Long Acting Beta 2 Agonist as of 2024)

Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans

Table 16. Global Long Acting Beta 2 Agonist Market Size by Region (US$ Million): 2020 VS 2024 VS 2031

Table 17. Global Long Acting Beta 2 Agonist Sales by Region (2020-2025) & (K Units)

Table 18. Global Long Acting Beta 2 Agonist Sales Market Share by Region (2020-2025)

Table 19. Global Long Acting Beta 2 Agonist Sales by Region (2026-2031) & (K Units)

Table 20. Global Long Acting Beta 2 Agonist Sales Market Share by Region (2026-2031)

Table 21. Global Long Acting Beta 2 Agonist Revenue by Region (2020-2025) & (US$ Million)

Table 22. Global Long Acting Beta 2 Agonist Revenue Market Share by Region (2020-2025)

Table 23. Global Long Acting Beta 2 Agonist Revenue by Region (2026-2031) & (US$ Million)

Table 24. Global Long Acting Beta 2 Agonist Revenue Market Share by Region (2026-2031)

Table 25. North America Long Acting Beta 2 Agonist Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)

Table 26. North America Long Acting Beta 2 Agonist Sales by Country (2020-2025) & (K Units)

Table 27. North America Long Acting Beta 2 Agonist Sales by Country (2026-2031) & (K Units)

Table 28. North America Long Acting Beta 2 Agonist Revenue by Country (2020-2025) & (US$ Million)

Table 29. North America Long Acting Beta 2 Agonist Revenue by Country (2026-2031) & (US$ Million)

Table 30. Europe Long Acting Beta 2 Agonist Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)

Table 31. Europe Long Acting Beta 2 Agonist Sales by Country (2020-2025) & (K Units)

Table 32. Europe Long Acting Beta 2 Agonist Sales by Country (2026-2031) & (K Units)

Table 33. Europe Long Acting Beta 2 Agonist Revenue by Country (2020-2025) & (US$ Million)

Table 34. Europe Long Acting Beta 2 Agonist Revenue by Country (2026-2031) & (US$ Million)

Table 35. Asia Pacific Long Acting Beta 2 Agonist Revenue by Region: 2020 VS 2024 VS 2031 (US$ Million)

Table 36. Asia Pacific Long Acting Beta 2 Agonist Sales by Region (2020-2025) & (K Units)

Table 37. Asia Pacific Long Acting Beta 2 Agonist Sales by Region (2026-2031) & (K Units)

Table 38. Asia Pacific Long Acting Beta 2 Agonist Revenue by Region (2020-2025) & (US$ Million)

Table 39. Asia Pacific Long Acting Beta 2 Agonist Revenue by Region (2026-2031) & (US$ Million)

Table 40. Latin America Long Acting Beta 2 Agonist Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)

Table 41. Latin America Long Acting Beta 2 Agonist Sales by Country (2020-2025) & (K Units)

Table 42. Latin America Long Acting Beta 2 Agonist Sales by Country (2026-2031) & (K Units)

Table 43. Latin America Long Acting Beta 2 Agonist Revenue by Country (2020-2025) & (US$ Million)

Table 44. Latin America Long Acting Beta 2 Agonist Revenue by Country (2026-2031) & (US$ Million)

Table 45. Middle East and Africa Long Acting Beta 2 Agonist Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)

Table 46. Middle East and Africa Long Acting Beta 2 Agonist Sales by Country (2020-2025) & (K Units)

Table 47. Middle East and Africa Long Acting Beta 2 Agonist Sales by Country (2026-2031) & (K Units)

Table 48. Middle East and Africa Long Acting Beta 2 Agonist Revenue by Country (2020-2025) & (US$ Million)

Table 49. Middle East and Africa Long Acting Beta 2 Agonist Revenue by Country (2026-2031) & (US$ Million)

Table 50. Global Long Acting Beta 2 Agonist Sales (K Units) by Type (2020-2025)

Table 51. Global Long Acting Beta 2 Agonist Sales (K Units) by Type (2026-2031)

Table 52. Global Long Acting Beta 2 Agonist Sales Market Share by Type (2020-2025)

Table 53. Global Long Acting Beta 2 Agonist Sales Market Share by Type (2026-2031)

Table 54. Global Long Acting Beta 2 Agonist Revenue (US$ Million) by Type (2020-2025)

Table 55. Global Long Acting Beta 2 Agonist Revenue (US$ Million) by Type (2026-2031)

Table 56. Global Long Acting Beta 2 Agonist Revenue Market Share by Type (2020-2025)

Table 57. Global Long Acting Beta 2 Agonist Revenue Market Share by Type (2026-2031)

Table 58. Global Long Acting Beta 2 Agonist Price (US$/Unit) by Type (2020-2025)

Table 59. Global Long Acting Beta 2 Agonist Price (US$/Unit) by Type (2026-2031)

Table 60. Global Long Acting Beta 2 Agonist Sales (K Units) by Application (2020-2025)

Table 61. Global Long Acting Beta 2 Agonist Sales (K Units) by Application (2026-2031)

Table 62. Global Long Acting Beta 2 Agonist Sales Market Share by Application (2020-2025)

Table 63. Global Long Acting Beta 2 Agonist Sales Market Share by Application (2026-2031)

Table 64. Global Long Acting Beta 2 Agonist Revenue (US$ Million) by Application (2020-2025)

Table 65. Global Long Acting Beta 2 Agonist Revenue (US$ Million) by Application (2026-2031)

Table 66. Global Long Acting Beta 2 Agonist Revenue Market Share by Application (2020-2025)

Table 67. Global Long Acting Beta 2 Agonist Revenue Market Share by Application (2026-2031)

Table 68. Global Long Acting Beta 2 Agonist Price (US$/Unit) by Application (2020-2025)

Table 69. Global Long Acting Beta 2 Agonist Price (US$/Unit) by Application (2026-2031)

Table 70. GSK Company Information

Table 71. GSK Description and Business Overview

Table 72. GSK Long Acting Beta 2 Agonist Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)

Table 73. GSK Long Acting Beta 2 Agonist Product

Table 74. GSK Recent Developments/Updates

Table 75. AstraZeneca Company Information

Table 76. AstraZeneca Description and Business Overview

Table 77. AstraZeneca Long Acting Beta 2 Agonist Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)

Table 78. AstraZeneca Long Acting Beta 2 Agonist Product

Table 79. AstraZeneca Recent Developments/Updates

Table 80. Chiesi Company Information

Table 81. Chiesi Description and Business Overview

Table 82. Chiesi Long Acting Beta 2 Agonist Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)

Table 83. Chiesi Long Acting Beta 2 Agonist Product

Table 84. Chiesi Recent Developments/Updates

Table 85. Boehringer Ingelheim Company Information

Table 86. Boehringer Ingelheim Description and Business Overview

Table 87. Boehringer Ingelheim Long Acting Beta 2 Agonist Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)

Table 88. Boehringer Ingelheim Long Acting Beta 2 Agonist Product

Table 89. Boehringer Ingelheim Recent Developments/Updates

Table 90. Novartis Company Information

Table 91. Novartis Description and Business Overview

Table 92. Novartis Long Acting Beta 2 Agonist Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)

Table 93. Novartis Long Acting Beta 2 Agonist Product

Table 94. Novartis Recent Developments/Updates

Table 95. Teva Company Information

Table 96. Teva Description and Business Overview

Table 97. Teva Long Acting Beta 2 Agonist Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)

Table 98. Teva Long Acting Beta 2 Agonist Product

Table 99. Teva Recent Developments/Updates

Table 100. Organon Company Information

Table 101. Organon Description and Business Overview

Table 102. Organon Long Acting Beta 2 Agonist Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)

Table 103. Organon Long Acting Beta 2 Agonist Product

Table 104. Organon Recent Developments/Updates

Table 105. Key Raw Materials Lists

Table 106. Raw Materials Key Suppliers Lists

Table 107. Long Acting Beta 2 Agonist Distributors List

Table 108. Long Acting Beta 2 Agonist Customers List

Table 109. Long Acting Beta 2 Agonist Market Trends

Table 110. Long Acting Beta 2 Agonist Market Drivers

Table 111. Long Acting Beta 2 Agonist Market Challenges

Table 112. Long Acting Beta 2 Agonist Market Restraints

Table 113. Research Programs/Design for This Report

Table 114. Key Data Information from Secondary Sources

Table 115. Key Data Information from Primary Sources

Table 116. Authors List of This Report

List of Figures

Figure 1. Product Picture of Long Acting Beta 2 Agonist

Figure 2. Global Long Acting Beta 2 Agonist Market Value Comparison by Type (2020-2031) & (US$ Million)

Figure 3. Global Long Acting Beta 2 Agonist Market Share by Type: 2024 & 2031

Figure 4. Serevent Product Picture

Figure 5. Foradil Product Picture

Figure 6. Other Product Picture

Figure 7. Global Long Acting Beta 2 Agonist Market Value by Application (2020-2031) & (US$ Million)

Figure 8. Global Long Acting Beta 2 Agonist Market Share by Application: 2024 & 2031

Figure 9. COPD

Figure 10. Asthma

Figure 11. Other

Figure 12. Global Long Acting Beta 2 Agonist Revenue, (US$ Million), 2020 VS 2024 VS 2031

Figure 13. Global Long Acting Beta 2 Agonist Market Size (2020-2031) & (US$ Million)

Figure 14. Global Long Acting Beta 2 Agonist Sales (2020-2031) & (K Units)

Figure 15. Global Long Acting Beta 2 Agonist Average Price (US$/Unit) & (2020-2031)

Figure 16. Long Acting Beta 2 Agonist Report Years Considered

Figure 17. Long Acting Beta 2 Agonist Sales Share by Manufacturers in 2024

Figure 18. Global Long Acting Beta 2 Agonist Revenue Share by Manufacturers in 2024

Figure 19. Global 5 and 10 Largest Long Acting Beta 2 Agonist Players: Market Share by Revenue in Long Acting Beta 2 Agonist in 2024

Figure 20. Long Acting Beta 2 Agonist Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2020 VS 2024

Figure 21. Global Long Acting Beta 2 Agonist Market Size by Region (US$ Million): 2020 VS 2024 VS 2031

Figure 22. North America Long Acting Beta 2 Agonist Sales Market Share by Country (2020-2031)

Figure 23. North America Long Acting Beta 2 Agonist Revenue Market Share by Country (2020-2031)

Figure 24. United States Long Acting Beta 2 Agonist Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 25. Canada Long Acting Beta 2 Agonist Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 26. Europe Long Acting Beta 2 Agonist Sales Market Share by Country (2020-2031)

Figure 27. Europe Long Acting Beta 2 Agonist Revenue Market Share by Country (2020-2031)

Figure 28. Germany Long Acting Beta 2 Agonist Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 29. France Long Acting Beta 2 Agonist Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 30. U.K. Long Acting Beta 2 Agonist Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 31. Italy Long Acting Beta 2 Agonist Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 32. Russia Long Acting Beta 2 Agonist Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 33. Asia Pacific Long Acting Beta 2 Agonist Sales Market Share by Region (2020-2031)

Figure 34. Asia Pacific Long Acting Beta 2 Agonist Revenue Market Share by Region (2020-2031)

Figure 35. China Long Acting Beta 2 Agonist Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 36. Japan Long Acting Beta 2 Agonist Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 37. South Korea Long Acting Beta 2 Agonist Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 38. India Long Acting Beta 2 Agonist Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 39. Australia Long Acting Beta 2 Agonist Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 40. China Taiwan Long Acting Beta 2 Agonist Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 41. Southeast Asia Long Acting Beta 2 Agonist Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 42. Latin America Long Acting Beta 2 Agonist Sales Market Share by Country (2020-2031)

Figure 43. Latin America Long Acting Beta 2 Agonist Revenue Market Share by Country (2020-2031)

Figure 44. Mexico Long Acting Beta 2 Agonist Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 45. Brazil Long Acting Beta 2 Agonist Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 46. Argentina Long Acting Beta 2 Agonist Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 47. Middle East and Africa Long Acting Beta 2 Agonist Sales Market Share by Country (2020-2031)

Figure 48. Middle East and Africa Long Acting Beta 2 Agonist Revenue Market Share by Country (2020-2031)

Figure 49. Turkey Long Acting Beta 2 Agonist Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 50. Saudi Arabia Long Acting Beta 2 Agonist Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 51. UAE Long Acting Beta 2 Agonist Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 52. Global Sales Market Share of Long Acting Beta 2 Agonist by Type (2020-2031)

Figure 53. Global Revenue Market Share of Long Acting Beta 2 Agonist by Type (2020-2031)

Figure 54. Global Long Acting Beta 2 Agonist Price (US$/Unit) by Type (2020-2031)

Figure 55. Global Sales Market Share of Long Acting Beta 2 Agonist by Application (2020-2031)

Figure 56. Global Revenue Market Share of Long Acting Beta 2 Agonist by Application (2020-2031)

Figure 57. Global Long Acting Beta 2 Agonist Price (US$/Unit) by Application (2020-2031)

Figure 58. Long Acting Beta 2 Agonist Value Chain

Figure 59. Channels of Distribution (Direct Vs Distribution)

Figure 60. Bottom-up and Top-down Approaches for This Report

Figure 61. Data Triangulation

Figure 62. Key Executives Interviewed

SELECT A FORMAT

Added to Cart

Single User

Electronic (PDF)

$2900

This license allows only one user to access the PDF.

Multi User

Electronic (PDF)

$4350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together

Enterprise User

Electronic (PDF)

$5800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report

Add to Cart

Buy Now (15% Discount)

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

Short Acting Beta Agonists Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Global Inhaled Asthma Medications Market Research Report 2024

Global Salbutamol Market Research Report 2024

Global Beta Blockers Market Research Report 2025

Global Ultra Long Acting Beta Agonist Market Research Report 2025

Global Beta Adrenergic Receptor Agonist Market Research Report 2024

Inhaler Medicine Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Global Orciprenaline Market Insights Forecast to 2030

Adrenergic Bronchodilator Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Levosalbutamol Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Global Salbutamol Sulfate Tablets Market Research Report 2024

Global Long acting Glucocorticoid Injection Market Research Report 2024

Global THR β Agonists Market Research Report 2024

Global Long acting GLP 1RA Market Research Report 2024

Global Levalbuterol Market Research Report 2024

Quick acting Asthma Medicine Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Anti Asthma Drugs Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Maintenance Inhaler Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Global β2 Adrenoceptor Agonists Market Research Report 2024

RELATED REPORTS

Global Vomiting Toxin Test Kit Market Research Report 2025

120 Pages

Type: Report

Code: QYRE-Auto-8H19532

Tue Jun 03 00:00:00 UTC 2025

Add to Cart

Global Blood Product Market Size, Manufacturers, Supply Chain, Sales Channel and Clients, 2025-2031

120 Pages

Type: Report

Code: QYRE-Auto-1089

Tue Jun 03 00:00:00 UTC 2025

Add to Cart

Global Neuro-Endoscopy Market Size, Manufacturers, Supply Chain, Sales Channel and Clients, 2025-2031

120 Pages

Type: Report

Code: QYRE-Auto-30R11881

Tue Jun 03 00:00:00 UTC 2025

Add to Cart

Global Colony Counters Market Size, Manufacturers, Supply Chain, Sales Channel and Clients, 2025-2031

120 Pages

Type: Report

Code: QYRE-Auto-14R5804

Tue Jun 03 00:00:00 UTC 2025

Add to Cart

aluates Reports

Support Contacts

U.S. (TOLL FREE)

+1 (425) 388-2538

[email protected]

THE COMPANY

OUR PRODUCTS

CUSTOMER SUPPORT

CONTACT
FAQ

POLICES

THE COMPANY

ABOUT US

CUSTOMER SUPPORT

CONTACT
FAQ

OUR PRODUCTS

POLICES

Sitemap - Privacy Policy - Terms & Conditions

	
		OSZAR »